Compare ASTRAZENECA PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NOVARTIS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NOVARTIS ASTRAZENECA PHARMA/
NOVARTIS
 
P/E (TTM) x 77.0 469.8 16.4% View Chart
P/BV x 21.7 27.3 79.6% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 ASTRAZENECA PHARMA   NOVARTIS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
NOVARTIS
Mar-18
ASTRAZENECA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,278758 168.6%   
Low Rs883579 152.4%   
Sales per share (Unadj.) Rs228.4228.4 100.0%  
Earnings per share (Unadj.) Rs10.431.7 32.7%  
Cash flow per share (Unadj.) Rs16.332.8 49.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs98.8297.1 33.2%  
Shares outstanding (eoy) m25.0024.69 101.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.9 161.6%   
Avg P/E ratio x104.221.1 494.9%  
P/CF ratio (eoy) x66.420.4 325.6%  
Price / Book Value ratio x10.92.2 486.2%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m27,00816,505 163.6%   
No. of employees `0001.40.7 203.0%   
Total wages/salary Rs m1,5351,445 106.2%   
Avg. sales/employee Rs Th4,210.98,441.3 49.9%   
Avg. wages/employee Rs Th1,132.22,163.6 52.3%   
Avg. net profit/employee Rs Th191.11,173.1 16.3%   
INCOME DATA
Net Sales Rs m5,7105,639 101.3%  
Other income Rs m1231,718 7.1%   
Total revenues Rs m5,8337,357 79.3%   
Gross profit Rs m463-63 -740.6%  
Depreciation Rs m14725 582.6%   
Interest Rs m055 0.0%   
Profit before tax Rs m4381,575 27.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179792 22.6%   
Profit after tax Rs m259784 33.1%  
Gross profit margin %8.1-1.1 -731.4%  
Effective tax rate %40.850.3 81.3%   
Net profit margin %4.513.9 32.7%  
BALANCE SHEET DATA
Current assets Rs m3,2099,522 33.7%   
Current liabilities Rs m2,0703,296 62.8%   
Net working cap to sales %20.0110.4 18.1%  
Current ratio x1.62.9 53.7%  
Inventory Days Days7237 197.6%  
Debtors Days Days3528 122.9%  
Net fixed assets Rs m79046 1,718.0%   
Share capital Rs m50123 40.5%   
"Free" reserves Rs m2,4197,213 33.5%   
Net worth Rs m2,4697,336 33.7%   
Long term debt Rs m00-   
Total assets Rs m4,60511,105 41.5%  
Interest coverage xNM29.5-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.5 244.2%   
Return on assets %5.67.6 74.5%  
Return on equity %10.510.7 98.2%  
Return on capital %17.722.2 79.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30061 494.3%   
Fx outflow Rs m2,0153,630 55.5%   
Net fx Rs m-1,715-3,570 48.1%   
CASH FLOW
From Operations Rs m881,610 5.5%  
From Investments Rs m-94687 -13.6%  
From Financial Activity Rs mNA-2,677 0.0%  
Net Cashflow Rs m-6-380 1.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 15.7 1.6 981.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   12,856 41,647 30.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WYETH LTD  IPCA LABS  ALKEM LABORATORIES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)

Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.

Related Views on News

ASTRAZENECA PHARMA Surges by 7%; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Oct 16, 2019 | Updated on Oct 16, 2019

ASTRAZENECA PHARMA share price has surged by 7% and its current market price is Rs 2,284. The BSE HEALTHCARE is up by 0.3%. The top gainers in the BSE HEALTHCARE Index is ASTRAZENECA PHARMA (up 7.0%). The top losers are LAURUS LABS LTD (down 0.1%) and PIRAMAL ENTERPRISES (down 0.1%).

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Oct 16, 2019 01:17 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - LUPIN COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS